AR 101

Drug Profile

AR 101

Alternative Names: AR-101-Aimmune-Therapeutics; Characterised-peanut-allergen-oral-immunotherapy-ARC; CPNA-Aimmune-Therapeutics; Peanut allergy immunotherapy - Aimmune Therapeutics; Peanut allergy OIT - Aimmune Therapeutics

Latest Information Update: 16 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Allergen Research Corporation
  • Developer Aimmune Therapeutics; Guys and St. Thomas Hospital NHS Trust
  • Class Allergens; Antiallergics; Food allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Peanut hypersensitivity

Most Recent Events

  • 28 May 2018 Safety and immunogenicity data from phase III PALISADE trial released by Aimmune Therapeutics
  • 11 Apr 2018 Allergen Research Corporation completes a phase II follow-on trial for Peanut hypersensitivity (In children, adolescents, adults) in USA (PO) (NCT02198664)
  • 27 Mar 2018 Aimmune Therapeutics plans the ARC005 clinical trial for Peanut hypersensitivity (In infants and children) in European Union second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top